Juvenile myelomonocytic leukemia (JMML) is a malignant disease of early childhood characterized by a hypersensitivity to granulocyte/macrophage colony-stimulating factor (GM-CSF). Mutations in RAS or PTPN11 are frequently detected in JMML patients. The SH2-containing inositol 5-phosphatase 1 (SHIP-1) is a negative regulator of GM-CSF signaling, and inactivation of SHIP-1 in mice results in a myeloproliferative disease. Here, we report the effects of SHIP-1 expression on GM-CSF-dependent proliferation and colony formation of human hematopoietic cells. After retroviral-mediated transduction of SHIP-1 into CD34 + cells from cord blood of healthy newborns or peripheral blood of JMML patients carrying mutations in KRAS2 or PTPN11, we observed a reduction in GM-CSF-dependent proliferation and colony formation. An enzymatically inactive form of SHIP-1 (D672A) had no effect. These data indicate that SHIP-1 can effectively block GM-CSF hypersensitivity in JMML progenitor cells with mutations in KRAS2 or PTPN11 and may be a useful approach for the treatment of JMML patients.
Introduction
The SH2-containing inositol 5-phosphatase 1 (SHIP-1), encoded by the INPP5D gene, is an important negative regulator of cytokine signaling.
1,2 SHIP-deficient mice develop a myeloproliferative disorder owing to an increased sensitivity of hematopoietic cells for several cytokines, including granulocyte macrophage-colonystimulating factor (GM-CSF). 3, 4 Mutations in the INPP5D gene have been detected in several patients with acute myeloid leukemia (AML) (seven out of 32) and in one patient with acute lymphoblastic leukemia (one out of nine), implicating mutated SHIP-1 in the pathogenesis of human acute leukemia. 5 One of the mutations detected in a patient with AML was located in a conserved motif within the catalytic domain causing a reduction in SHIP-1 activity. 6 These data suggest a possible tumor suppressor function of SHIP-1. Restoration of SHIP-1 activity in a human SHIP-1-deficient leukemia cell line (Jurkat) resulted in a reduced proliferation owing to an increased transit time through the G1 phase of the cell cycle. 7 Juvenile myelomonocytic leukemia (JMML) is a malignant hematopoietic disease of early childhood characterized by excessive proliferation of the myeloid and monocytic lineage. This abnormal myeloproliferation appears to be the result of a selective hypersensitivity of the myeloid JMML progenitor cells to GM-CSF. 8 The JMML-initiating cell has been identified within the CD34 + immature cell population from JMML patients. 9 The growth of JMML cells can be reduced in vitro in cell culture experiments and in vivo in a mouse model by anti-GM-CSF antibodies or a GM-CSF antagonist indicating that GM-CSF is an important factor for the proliferation of JMML cells. 10, 11 Mutations in genes encoding Ras proteins, that is, NRAS or KRAS2 (B20%) 12 or in genes encoding Ras regulators, that is, PTPN11 (B35%) 13 and NF1 (B25%) 14 have been detected in JMML patients. Together, these data indicate that constitutive activation of GM-CSF receptor-RAS signaling plays an important role in the pathogenesis of JMML. In this report, we describe the effects of SHIP-1 on the GM-CSF-dependent proliferation and colony formation of human CD34 + hematopoietic cells from normal donors and from two patients with JMML carrying mutations either in the KRAS2 or PTPN11 gene.
SHIP-1 or an enzymatic inactive form of SHIP-1 (D672A) was expressed in CD34 + cells by using retroviral expression vectors co-expressing enhanced green fluorescent protein (EGFP). After retroviral transduction, EGFP-positive cells were sorted and plated in medium supplemented with GM-CSF. Expression of SHIP-1 and EGFP caused a 69721% reduction in the GM-CSFdependent proliferation of normal CD34
+ cord blood (CB) cells relative to CD34
+ cells transduced with a vector carrying EGFP, only (Pp0.01) (Figure 1a) . A similar reduction of proliferation was observed after expression of SHIP-1 in CD34
+ cells from JMML-1 (75722%) and JMML-2 (70711%) (Pp0.01) (Figure 1a) . Expression of the enzymatic inactive form of SHIP-1 (D672A) did not significantly reduce the proliferation of any of the CD34 + cells, indicating that the inhibitory effect of SHIP-1 on the GM-CSF-dependent growth of normal and leukemic CD34 + cells is dependent on the enzymatic activity of SHIP-1 (Figure 1a) .
The inhibitory effect of SHIP-1 on the GM-CSFdependent proliferation of JMML CD34 + cells was further analyzed using various concentrations of GM-CSF. CD34
+ cells from patient JMML-2 showed a weak proliferation in serum free medium, which increased by the addition of GM-CSF in a concentration-dependent manner (Figure 1b ). SHIP-1 was able to counteract the GM-CSF-dependent increase in the proliferation of JMML-2 cells at low concentrations of GM-CSF almost completely and at higher concentrations of GM-CSF (10 ng/ml) by 70711% (Figure 1b) . These data demonstrate that SHIP-1 can efficiently counteract the GM-CSFdependent proliferation of primary CD34 + cells from a patient with JMML.
Next, we analyzed the effect of SHIP-1 on the colony formation of normal and JMML hematopoietic progenitor cells. By using the same retroviral vectors as described above, SHIP-1 or the enzymatically inactive mutant of SHIP-1 (D672A) were expressed in CD34 + cells from CB of normal donors (n ¼ 3) and in CD34 + cells from peripheral blood (PB) of the two JMML patients. We further analyzed why approximately 50% of the SHIP-1-transduced cells were still able to form colonies. The level of SHIP-1 expression achieved in the transduced cell may decide whether a cell is still able to proliferate and form a colony or not. To test this hypothesis, CD34
+ cells from CB of normal donors were transduced with the retroviral co-expression vector containing EGFP or EGFP+SHIP-1, as described above. Transduced cells were sorted in EGFP À cells (G1), low EGFP + cells (G2) and high EGFP + cells (G3) (Figure 3a ). In comparison with the EGFP-transduced cells, GM-CSFdependent colony formation of the EGFP+SHIP-1-transduced cells was much strongly reduced in the high EGFP + cells (G3) (8173%) than in the low EGFP + cells (G2) (4675%) (Pp0.001) (Figure 3b ). These data demonstrate a concentration-dependent effect of SHIP-1 on the reduction of GM-CSF-dependent colony growth and strongly suggest that the inhibitory effect of SHIP-1 on the proliferation of CD34 + cells is dependent on the amount of SHIP expression.
In summary, our data indicate that the expression of SHIP-1 caused a reduction of the GM-CSF-dependent proliferation and colony formation of CD34 + cells 
Effects of SHIP-1 on JMML cells
A Metzner et al derived from CB of full-term healthy neonate and from PB of two patients with JMML. The inhibitory effect of SHIP-1 on the hypersensitivity of JMML cells to GM-CSF suggests a potential role of SHIP-1 for gene therapy of patients with JMML. However, SHIP-1 may be toxic because colony growth of normal CD34 + cells was also reduced by SHIP-1, even though not that strong as in the JMML leukemia cells (36 versus 51%, respectively). It may be possible that a JMML patient after SHIP-1 gene therapy will have enough hematopoietic cells to build a functional blood system, whereas the reduced leukemia cell load may improve survival and/or response in combination with chemotherapy or another specific therapy (i.e. inhibitors for Ras). In addition, the currently used chemotherapy to treat children with JMML is very toxic with severe side effects and this disease has a bad prognosis. The disease is uniformly fatal when treated with conventional chemotherapy, but even after bone marrow transplantation many patients relapse and approximately only 50% of patients with JMML can be cured. 15 These data indicate the urgent need for any new treatment strategy for JMML patients.
Materials and methods

Patient samples
Umbilical cord blood (CB) from healthy newborns and PB from two children with JMML (designated JMML-1 and JMML-2) were obtained after informed consent and by a protocol approved by the ethical committee of the medical board of Hamburg (OB/7/01). Both JMML patients fulfilled the diagnostic criteria defined by the International working group on JMML. 16 Mutational analysis identified a PTPN11 alteration in exon 3 (n226; G4A) in JMML1, and a KRAS2 mutation in exon 1 (n35; G4T) in JMML2. Progenitor cultures performed in JMML1 demonstrated a consistent GM-CSF hypersensitivity of CFU-GM. Mononuclear cells were collected from CB and PB by density centrifugation on Lymphoprep + cells were enriched to more than 80% purity with magnetic beads according to the protocol of the manufacturer (StemCell Technologies, CellSystems, St Katharinen, Germany).
Retroviral vectors and generation of pseudotyped viral particles
A human SHIP-1 cDNA was cloned from a factorindependent mutant of the erythroleukemia cell line TF-1 as described previously. 7 A SHIP-1 mutant without enzymatic activity was created by exchanging the aspartic acid at position 672 in the second conserved motif of the inositol phosphatase domain to alanine (D672A). The resulting mutant did not reveal any detectable enzymatic activity in an in vitro inositol 5-phosphatase assay using Ins(1,3,4,5)P 4 as substrate (data not shown). The cDNAs of SHIP-1 and SHIP-1(D672A) were subcloned in the Not I site of the retroviral expression vector pSF91-I-eGFP-PRE. 17 The packaging cell line Phoenix-GP was cultivated in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 2 mM glutamine and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid, pH 7.8. Pseudotyped retroviruses were generated by transient lipofectamine-mediated co-transfection with 5 mg of the retroviral vector together with 5 mg of a plasmid encoding the envelope protein of feline endogenous virus (RD114) 18 and 10 mg of the plasmid encoding gag and pol proteins in the Phoenix-GP packaging cell line. Virus supernatants were collected 48, 72 and 96 h after transfection, filtered and stored at À801C until used. The titer was determined according to the EGFP fluorescence by serial dilutions of the viral supernatants on human HT1080 cells. Titers ranged from 1 Â 10 6 to 3 Â 10 6 infectious particles per millilitre.
Retroviral transduction of CD34 + cells
Enriched CD34 + cells (5 Â 10 5 ) were cultured in 2 ml serum-free medium (StemSpan, Stemcell Technologies, CellSystems, St Katharinen, Germany) supplemented with Flt3 ligand (100 ng/ml), stem cell factor (100 ng/ ml), thrombopoietin (20 ng/ml) and IL-6 (20 ng/ml) (PeproTech EC LTD, CellSystems, St Katharinen, Germany). After cultivation for 48 h, 5 Â 10 5 of the prestimulated CD34 + cells were cultured in 1 ml serum-free medium in a six-well plate that had been (i) pretreated with 2% bovine serum albumin in phosphate-buffered saline (PBS) (ii) precoated with retronectin (10 mg/cm 2 , Takara, Otsu, Japan) and (iii) preloaded with virus particles. After 24 h, the CD34 + cells were transferred into a new virus-preloaded well for a second infection. Virus preloading was performed three to four times by centrifugation of 1 ml viral supernatant for 25 min at 41C at 800 g each time. Transduction was performed at a multiplicity of infection (MOI) of 1-2.
Flow cytometry and cell sorting
After transduction, cells were washed and resuspended in 500 ml PBS. Fluorescence-activated cell sorting (FACS) with a FACSAria (Becton Dickinson, Heidelberg, Germany) was performed to isolate transduced cells expressing the EGFP. Sorted cells were collected into 0.5 ml Eppendorf tubes containing stem span medium.
In vitro culture and colony-forming assays Sorted cells were cultured in 96-well plates at 1 Â 10 3 cells per 100 ml serum-free expansion medium (SFEM) (StemCell Technologies, CellSystems, St Katharinen, Germany) supplemented with different concentrations of human recombinant GM-CSF. The number of cells in each well was counted 10 days after plating. The number of colonies derived from CFU-GM were determined by plating sorted cells at 1 Â 10 3 cells per milliliter in serumcontaining methyl cellulose medium (MethoCult, StemCell Technologies, CellSystems, St Katharinen, Germany), supplemented with recombinant GM-CSF (10 ng/ml). Colonies were counted after 14 days of incubation at 371C.
Mutation analysis
Mutation analysis of PTPN11 and RAS genes were performed as described previously. 19 
Statistical analysis
Data are presented as mean values with s.d. from triplicates of cell assays. A modified t-test (Lord's u-test nn ) has been applied to test the significance level P for differences between groups; that is, cells expressing EGFP versus EGFP+SHIP-1 or EGFP versus EGFP+SHIP-1(D672A). This test replaces the s.d. in the t-test by the range. 20 
